GENERAL ACCOUNTING OFFICE

Advisory Council on Government Auditing Standards; Notice of Meeting

The Advisory Council on Government Auditing Standards will meet on Monday, November 24, 1997, from 9:00 a.m. to 5:00 p.m., and Tuesday, November 25, 1997, from 8:30 a.m. to 3:00 p.m., in room 7C13 of the General Accounting Office building, 441 G St., NW., Washington, D.C.

The Advisory Council on Government Auditing Standards will hold a meeting to discuss issues that may impact Government Auditing Standards. Any interested person may attend the meeting as an observer. Council discussions and reviews are open to the public.

For further information contact: Marcia Buchanan, Assistant Director, Government Auditing Standards, AIMD, (202) 512–9321.

Dated: November 7, 1997.

Marcia B. Buchanan,

Assistant Director.

[FR Doc. 97–29911 Filed 11–13–97; 8:45 am]

BILLING CODE 1610–02–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

National Center for Health Statistics (NCHS), Data Policy and Standards Staff; Meeting

Name: ICD–9–CM Coordination and Maintenance (C&M) Committee meeting.

Times and Dates: 9 a.m.–5 p.m. December 4, 1997; 9 a.m.–5 p.m. December 5, 1997.

Place: The Health Care Financing Administration, Auditorium, 7500 Security Boulevard, Baltimore, Maryland.

Status: Open to the public. In the interest of security, non-government employees must show a photo I.D., and sign-in to gain entrance to the building.

Purpose: The ICD–9–CM Coordination and Maintenance Committee will hold its final meeting of the 1997 cycle on Thursday, December 4 (Vol. 3 (Procedures)), and Friday, December 5 (Volumes 1 and 2 (Diagnosis)). The C&M meeting is a public forum for the presentation of proposed modifications to the International Classification of Diseases, Ninth-Revision, Clinical Modification.

Matters To Be Discussed: Agenda items will include:

Injury aftercare status
Palliative care
Ostomy complications
Late effects of CVA
Diabetes
Group B strep carrier status
Complications of artificial skin replacement
Update on ICD–10 Procedure Coding System
Platelet inhibitors
Artificial skin grafts
Stereotactic radiosurgery
Cardiomyostimulator
Percutaneous vascular puncture closure
Amniofusion
Injection or infusion of thrombolytic agent
Addenda

Agenda items are subject to change as priorities dictate.

Contact Person for Additional Information: Amy L. Blum, 301/436–7050 ext. 164 (diagnosis), or Amy Gruber 410/786–1542 (procedures), NCHS, CDC, Presidential Building, 6525 Belcrest Road, Hyattsville, Maryland 20782.

Dated: November 7, 1997.

John C. Burckhardt,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97–29969 Filed 11–13–97; 8:45 am]

BILLING CODE 4160–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

The National Immunization Program (NIP) of the Centers for Disease Control and Prevention (CDC); Meeting

Name: Adolescent Immunization Meeting.

Time and Date: 7:30 a.m.–4 p.m. December 4, 1997.

Place: J.W. Marriott Hotel, Lenox, 3300 Lenox Road, NE Atlanta, Georgia 30326. Telephone 404/262–3344, fax 404/262–8803.

Status: The meeting is open to the public subject to the availability of conference room space. The meeting will be a round table discussion with public and private medical providers and experts who deal with adolescent health and immunization issues. Written comments will be accepted during the meeting or at the address below. Attendees must provide and pay for their own travel expenses.

Purpose: The meeting will bring together a small group of public and private medical experts, in adolescent health and immunization, to collaborate with the CDC in developing adolescent immunization disease reduction and coverage goals/objectives.

Matters To Be Discussed: CDC speakers will present background information; sample goals/objectives; year 2000 and possible 2010 Healthy People objectives; and other adolescent immunization health information. In addition, CDC speakers will describe vaccine-preventable diseases associated with adolescents and estimated immunization coverage levels.

Specific agenda items include adolescent immunization coverage goals; coverage estimates for childhood and adolescent immunization; adolescent disease reduction goals; epidemiology of vaccine preventable diseases in adolescents; implementation perspectives; HEDIS 3.0 adolescent immunization measures; and managed care organization adolescent immunization policies.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Edith Gary, Health Services Research and Evaluation Branch, Immunization Services Division, CDC, NIP, 1600 Clifton Road, NE, M/S E–52, Atlanta, Georgia 30333. Telephone 404/639–8209, fax 404/639–8615, e-mail exg1@cdc.gov.

Dated: November 7, 1997.

John C. Burckhardt,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97–29970 Filed 11–13–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97N–0431]

Iatric Corp.; Revocation of Product License for Coccidioidin, USP (BioCox)

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the revocation of the biological product license issued to Iatric Corp., Tempe, AZ, for the manufacture of Coccidioidin, USP (BioCox). In a letter to FDA dated May 13, 1997, Iatric Corp. voluntarily requested revocation of its product license for Coccidioidin, USP (BioCox). In a letter dated June 25, 1997, FDA informed the firm that its product license for Coccidioidin, USP (BioCox) was revoked.

DATES: The revocation of the product license became effective June 25, 1997.

FOR FURTHER INFORMATION CONTACT: Astrid L. Szeto, Center for Biologics Evaluation and Research (HFM–17), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–827–6210.

SUPPLEMENTARY INFORMATION: FDA has revoked the product license issued to Iatric Corp., 2330 South Industry Park Ave., Tempe, AZ 85282, for the manufacture of Coccidioidin, USP (BioCox).

FDA inspected Iatric Corp. on April 7 through 11, 1997. The inspection of the facility revealed serious deviations from applicable Federal regulations. The inspection also included a concurrent investigation concerning the interstate distribution of the product. The deficiencies noted included, but were not limited to, the following: (1) Failure